Status:
RECRUITING
Impact of Cerebellar TMS on Brain and Cognitive Functions in Schizophrenia: a Pilot Study
Lead Sponsor:
Northwell Health
Conditions:
Schizophrenia
Cerebellar Function
Eligibility:
All Genders
18-60 years
Phase:
NA
Brief Summary
This is a single-site, sham-controlled, randomized trial in a total of 40 subjects between ages 18 and 60 years with schizophrenia. This study will investigate the effects of 4-week rTMS treatment on ...
Eligibility Criteria
Inclusion
- Male or female subjects 18 to 60 years of age
- DSM-V diagnosis of schizophrenia spectrum disorders
- Competent to provide informed consent
Exclusion
- Lifetime DSM-V diagnosis of an Axis-I disorder other than schizophrenia spectrum disorders
- Lifetime diagnosis of ataxia or other cerebellar disorders
- Lifetime diagnosis of mental retardation, dementia, Alzheimer's disease, Parkinson's disease, Huntington's disease, or other neurodegenerative disorders
- Any active general medical condition or CNS disease which can affect cognition or response to treatment
- Substance dependence or abuse in the past six months
- Seizure history
- TMS within three months or ECT within six months
- Pregnancy as indicated by self-report
- MRI contraindications
Key Trial Info
Start Date :
August 18 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 31 2027
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT05389787
Start Date
August 18 2022
End Date
August 31 2027
Last Update
September 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zucker Hillside Hospital
New York, New York, United States, 11004